HQL

Tekla Life Sciences Investors (HQL)

$17.14

Last Close (24-hour delay)

Profit since last BUY44.89%

Consider higher Upturn Star rating

BUY since 135 days

• BUY Advisory
• SELL Advisory (Profit)
• SELL Advisory (Loss)

• Profit
• Loss
• Pass (Skip investing)

Stock price based on last close

*as per simulation
(see disclosures)

Upturn Star Rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock

Historic Profit 58.5%

Avg. Invested days 52

Today’s Advisory Consider higher Upturn Star rating

Upturn Star Rating

Upturn Advisory Performance 3.0

Stock Returns Performance 3.0

Profits based on simulation

Last Close 12/12/2025

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.